Journals / Türk Kardiyoloji Derneği Arşivi / 2017 / Cilt: 45 - Sayı: 3

Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study

Akut miyokart enfarktüslü hastalarda yüksek doz atorvastatin ile yüksek doz rosuvastatinin oksidatif stres üzerine etkilerinin karşılaştırılması: Bir pilot çalışma

Pages
235–243
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Rosuvastatin affected HDL-C level more favorably than atorvastatin

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Oxidative stress is increased in patients with acute myocardial infarction (AMI).
📊
Key Findings & Data:The aim of the present study was to compare the effects of atorvastatin and rosuvastatin on oxidative status by investigating serum paraoxonase, serum arylesterase, total oxidant status, total antioxidant status (TAS) and oxidative stress index (OSI) in patients with AMI.Methods: Seventy patients with AMI were randomized into 2 groups; total of 55 patients (19 females, 36 males) aged 32 to 86 years completed the study and were included in the analysis.
💡
Conclusion & Impact:Rosuvastatin affected HDL-C level more favorably than atorvastatin
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Oxidative stress is increased in patients with acute myocardial infarction (AMI). Statins reduce oxidative stress independent of their effect in reducing low-density lipoprotein cholesterol (LDL-C). The aim of the present study was to compare the effects of atorvastatin and rosuvastatin on oxidative status by investigating serum paraoxonase, serum arylesterase, total oxidant status, total antioxidant status (TAS) and oxidative stress index (OSI) in patients with AMI.Methods: Seventy patients with AMI were randomized into 2 groups; total of 55 patients (19 females, 36 males) aged 32 to 86 years completed the study and were included in the analysis. Patients were treated with 80 mg atorvastatin or 40 mg rosuvastatin for 4 weeks. Lipid parameters and parameters of oxidative status were measured at admission and after 4-week statin treatment.Results: After 4-week treatment, atorvastatin and rosuvastatin were associated with significant reduction in TAS, OSI, total cholesterol, and LDL-C levels. Serum paraoxonase level was significantly increased in both groups, while highdensity lipoprotein cholesterol (HDL-C) level was significantly reduced in atorvastatin group. No statistically significant differences were found between atorvastatin and rosuvastatin in terms of actual difference in oxidative stress parameters.Conclusion: Atorvastatin and rosuvastatin have similar effects on oxidative status in patients with AMI. Rosuvastatin affected HDL-C level more favorably than atorvastatin

Özet

Amaç: Akut miyokart enfarktüslü (AME) hastalarda oksidatif stres artmıştır. Statinler oksidatif stresi, düşük yoğunluklu lipoprotein kolesterol düşürücü etkilerinden bağımsız olarak azaltırlar. Bu çalışmanın amacı, AME'li hastalarda atorvastatin ve rosuvastatinin oksidatif durumu üzerine olan etkilerini, serum paraoksonaz, serum arilesteraz, toplam oksidan durum ve oksidatif stres indeksini araştırarak karşılaştırmaktır.Yöntemler: Yetmiş AME'li hasta iki gruba randomize edildi. Çalışmayı tamamlayan 32-86 yaş arası 55 hastanın (19 kadın, 36 erkek) verileri analiz edildi. Hastalar dört hafta boyunca 80 mg atorvastatin veya 40 mg rosuvastatin ile tedavi edildi. Lipit parametreleri ve oksidatif durum parametreleri başvuruda ve dört haftalık statin tedavisi sonrasında ölçüldü.Bulgular: Dört haftalık tedavi sonrasında atorvastatin ve rosuvastatin, toplam antioksidan durumda, oksidatif stres indeksinde, toplam kolesterol ve düşük yoğunluklu lipoprotein kolesterol düzeylerinde anlamlı azalma ile ilişkili bulundu. Serum paraoksonaz düzeyleri her iki grupta da anlamlı olarak artarken yüksek yoğunluklu lipoprotein kolesterol düzeyi, atorvastatin grubunda anlamlı olarak azaldı. Oksidatif stres parametrelerindeki değişim bakımından atorvastatin ve rosuvastatin arasında istatistiksel olarak anlamlı bir fark saptanmadı.Sonuç: Akut miyokart enfarktüslü hastalarda oksidatif durum üzerine atorvastatin ve rosuvastatinin benzer etkileri vardır. Rosuvastatin yüksek yoğunluklu lipoprotein kolesterol düzeyini atorvastatine göre daha olumlu etkilemektedir

🔖

Cite This Article

KİLİT, C., KOÇAK, F. E., KİLİT, T. P. (2022). Comparison of the effects of high-dose atorvastatin and high-dose rosuvastatin on oxidative stress in patients with acute myocardial infarction: A pilot study. Türk Kardiyoloji Derneği Arşivi, Cilt: 45 - Sayı: 3, 235–243. https://ajindex.com/articles/632271

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002;156:274–85
  2. Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis 2001;155:347–57
  3. Beltowski J. Statins and modulation of oxidative stress. Toxicol Mech Methods 2005;15:61–92
  4. Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569–619
  5. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551–67
  6. Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447–52
  7. Landmesser U, Bahlmann F, Mueller M, Spiekermann S, Kirchhoff N, Schulz S, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005;111:2356–63
  8. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009;119:131–8
  9. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–9
  10. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005;38:1103–11
  11. Akcilar R, Akcilar A, Savran B, Ayada C, Kocak C, Kocak FE, et al. Effects of ukrain in rats with intestinal ischemia and reperfusion. J Surg Res 2015;195:67–73
  12. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126–38
  13. Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3·1·1·2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 1992;30:391–5
  14. Patil N, Chavan V, Karnik ND. Antioxidant st